178 related articles for article (PubMed ID: 624904)
21. Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator.
Gigli I; Fujita T; Nussenzweig V
Proc Natl Acad Sci U S A; 1979 Dec; 76(12):6596-600. PubMed ID: 293746
[TBL] [Abstract][Full Text] [Related]
22. [Binding of activated C3b component with complement effector].
Kozlov LV; Rostovtseva LI; Lomaka TS; Sutovskaia NS
Bioorg Khim; 1985 Jun; 11(6):762-8. PubMed ID: 3849970
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of the alternative C3 convertase and classical C5 convertase of complement by group A streptococcal M protein.
Hong K; Kinoshita T; Takeda J; Kozono H; Pramoonjago P; Kim YU; Inoue K
Infect Immun; 1990 Aug; 58(8):2535-41. PubMed ID: 2142480
[TBL] [Abstract][Full Text] [Related]
24. C3 convertase of the alternative complement pathway. Demonstration of an active, stable C3b, Bb (Ni) complex.
Fishelson Z; Pangburn MK; Müller-Eberhard HJ
J Biol Chem; 1983 Jun; 258(12):7411-5. PubMed ID: 6553050
[TBL] [Abstract][Full Text] [Related]
25. Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement.
Farries TC; Lachmann PJ; Harrison RA
Biochem J; 1988 Aug; 253(3):667-75. PubMed ID: 3140783
[TBL] [Abstract][Full Text] [Related]
26. Activation of the classical pathway of complement by the C3NeF-stabilized cell-bound amplification convertase.
Daha MR; van Es LA
J Immunol; 1979 Mar; 122(3):801-5. PubMed ID: 448075
[TBL] [Abstract][Full Text] [Related]
27. Regulation of C5 convertase activity by properdin, factors B and H.
Weiler JM
Immunol Res; 1989; 8(4):305-15. PubMed ID: 2531781
[No Abstract] [Full Text] [Related]
28. Purification and functional analysis of the polymorphic variants of the C3b/C4b receptor (CR1) and comparison with H, C4b-binding protein (C4bp), and decay accelerating factor (DAF).
Seya T; Holers VM; Atkinson JP
J Immunol; 1985 Oct; 135(4):2661-7. PubMed ID: 3161944
[TBL] [Abstract][Full Text] [Related]
29. A molecular basis of activation of the alternative pathway of human complement.
Austen KF; Fearon DT
Adv Exp Med Biol; 1979; 120B():3-17. PubMed ID: 390986
[TBL] [Abstract][Full Text] [Related]
30. Preferential inactivation of the C5 convertase of the alternative complement pathway by factor I and membrane cofactor protein (MCP).
Seya T; Okada M; Matsumoto M; Hong KS; Kinoshita T; Atkinson JP
Mol Immunol; 1991 Oct; 28(10):1137-47. PubMed ID: 1833639
[TBL] [Abstract][Full Text] [Related]
31. Stabilization of the amplification convertase of complement by monoclonal antibodies directed against human factor B.
Daha MR; Deelder AM; Van Es LA
J Immunol; 1984 May; 132(5):2538-42. PubMed ID: 6232321
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of classical C5 convertase in the complement system by factor H.
Ito S; Tamura N
Immunology; 1983 Dec; 50(4):631-5. PubMed ID: 6228516
[TBL] [Abstract][Full Text] [Related]
33. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3.
Pangburn MK; Schreiber RD; Müller-Eberhard HJ
J Exp Med; 1981 Sep; 154(3):856-67. PubMed ID: 6912277
[TBL] [Abstract][Full Text] [Related]
34. An inherited defect in the C3 convertase, C3b,Bb, associated with glomerulonephritis.
Marder HK; Coleman TH; Forristal J; Beischel L; West CD
Kidney Int; 1983 May; 23(5):749-58. PubMed ID: 6553695
[TBL] [Abstract][Full Text] [Related]
35. Further evidence for the antibody nature of C3 nephritic factor (C3NeF).
Daha MR; van Es LA
J Immunol; 1979 Aug; 123(2):755-8. PubMed ID: 379217
[TBL] [Abstract][Full Text] [Related]
36. Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms.
Fearon DT; Austen KF
Proc Natl Acad Sci U S A; 1977 Apr; 74(4):1683-7. PubMed ID: 266208
[TBL] [Abstract][Full Text] [Related]
37. Reconstitution of C5 convertase of the alternative complement pathway with isolated C3b dimer and factors B and D.
Hong K; Kinoshita T; Pramoonjago P; Kim YU; Seya T; Inoue K
J Immunol; 1991 Mar; 146(6):1868-73. PubMed ID: 2005382
[TBL] [Abstract][Full Text] [Related]
38. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb.
Fujita T; Inoue T; Ogawa K; Iida K; Tamura N
J Exp Med; 1987 Nov; 166(5):1221-8. PubMed ID: 2445886
[TBL] [Abstract][Full Text] [Related]
39. The low C5 convertase activity of the C4A6 allotype of human complement component C4.
Kinoshita T; Dodds AW; Law SK; Inoue K
Biochem J; 1989 Aug; 261(3):743-8. PubMed ID: 2803239
[TBL] [Abstract][Full Text] [Related]
40. C5 convertase of the alternative complement pathway: covalent linkage between two C3b molecules within the trimolecular complex enzyme.
Kinoshita T; Takata Y; Kozono H; Takeda J; Hong KS; Inoue K
J Immunol; 1988 Dec; 141(11):3895-901. PubMed ID: 3183384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
